Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Hypertension. 2009 Jul 6;54(3):516–523. doi: 10.1161/HYPERTENSIONAHA.109.134197

Figure 2.

Figure 2

Meta-analysis showing the effect of vildagliptin on the risk of angioedema, in all patients, those taking an angiotensin-converting enzyme (ACE) inhibitor concurrently, and those taking an angiotensin-receptor blocker (ARB) concurrently. Data are presented as odds ratios and 95% confidence intervals. Odds ratios were estimated using the Peto method, in which all studies with a comparator treatment arm and an event in at least one arm were included. This analysis was conducted using both fixed effect (Fixed) and random effect (Random) models. * NSI indicates not sufficient information.

HHS Vulnerability Disclosure